

Influenza Session

Emmanuel (Chip) Walter, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
October 25, 2018

Influenza Work Group

ACIP Members

Emmanuel (Chip) Walter (Chair)

Robert Atmar

Hank Bernstein

Peter Szilagyi

***Ex Officio* Members**

Sarah Browne (FDA)

Cynthia Nolletti (FDA)

Roshan Ramanathan (FDA)

Chris Roberts (NIH)

Consultants

Jeff Duchin

Wendy Keitel

Ruth Karron

Jamie Loehr

Ed Belongia

Liaison Representatives

Kevin Ault (ACOG)

Sarah Coles (AAFP)

Sarah Despres (Consumer Representative)

Buddy Creech (PIDS)

Sandra Fryhofer (ACP; AMA)

Ian Gemmill (NACI)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Flor Munoz (AAP)

Kathy Neuzil (IDSA)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Patsy Stinchfield (NAPNAP)

Rob Stirling (NACI)

Tamara Sheffield (AHIP)

Matthew Zahn (NACCHO)

Recap of Influenza Session, June 2018

- 2017-18 influenza vaccine effectiveness update
- 2017-18 influenza vaccine safety update
- Presentation of the SOMNIA study, a multinational study of narcolepsy following adjuvanted monovalent pandemic H1N1 influenza vaccines
- Presentation from Seqirus of results of a study of adjuvanted quadrivalent inactivated influenza vaccine in young children
- Summary of the 2018-19 recommendations

Workgroup Activities/Discussions Since February 2018

- Publication of the 2018-19 ACIP influenza vaccine statement
- Presentation of the PREVENT study of effectiveness of influenza vaccine in preventing hospitalization among pregnant women
- Presentation of study of Fluzone Quadrivalent (IIV4, Sanofi Pasteur) at a 0.5mL dose for children aged 6 through 35 months

Updated Labeling Information

- ***Afluria*** (IIV3, Seqirus) and ***Afluria Quadrivalent*** (IIV4, Seqirus):
 - Previously licensed for ages 5 years and older
 - In October 2018, age indication expanded to ages 6 months and older
 - Dose volume
 - Ages 6 through 35 months: 0.25 mL
 - Ages 36 months (3 years) and older: 0.5 mL

- Note: Five IIVs now licensed for 6 through 35 months*:
 - ***Fluarix Quadrivalent*** (IIV4, GSK) 0.5mL
 - ***FluLaval Quadrivalent*** (IIV4, GSK) 0.5 mL
 - ***Fluzone Quadrivalent*** (IIV4, Sanofi Pasteur) 0.25 mL
 - ***Afluria*** (IIV3, Seqirus) 0.25 mL
 - ***Afluria Quadrivalent*** (IIV4, Seqirus) 0.25 mL

*Dose for persons aged three and older is 0.5mL for all IIVs

Agenda Overview

- **Influenza Vaccine Effectiveness in Preventing Influenza-Associated Hospitalizations during Pregnancy**
 - Dr. Mark Thompson (CDC/NCIRD/Influenza Division)
- **Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Months**
 - Dr. Monica Mercer (Sanofi Pasteur)